Camlin Fine Sciences Ltd Q2 FY2024 Concall Summary

Key Takeaways

• A quarter defined by shutdowns, not demand: Revenue fell 16% YoY as the temporary closure of the Italy Diphenol facility and delayed vanillin ramp-up overwhelmed strong blends growth.
• The vanillin bet is now a waiting game: The composite plant is producing and bids are out, but Chinese oversupply has crushed prices and pushed the payback period from 3 years to 4–5 years.
• Blends is the quiet compounder: North America and Brazil delivered excellent growth, with the pet food and rendering business providing sticky, service-driven revenue that now exceeds 40% of the mix.
• The balance sheet got a quiet win: Net debt fell from ₹680 crores to ₹565 crores after the IFC FCCB conversion, even as the P&L took the full weight of the vanillin plant's depreciation and interest.
• What to watch next quarter: Whether the vanillin contract bids close favorably by end of Q3, whether Hydroquinone price firming allows an Italy restart in Q4, and whether the margin slide finds a floor.

The Vanillin Gamble: Capacity Meets a Price War

• The plant is ready, the market is not: The composite vanillin plant at Dahej was capitalized in January 2023 and began producing both methyl and ethyl vanillin on a campaign basis in August, with commercial-quality samples now with prospective customers. But Chinese competitors have flooded the market, driving prices well below sustainable levels.
• Ethyl vanillin production underway: The plant will run ethyl vanillin through end of November 2023 before switching back to methyl vanillin, building roughly 200 tons of inventory worth about ₹20 crores, on top of ₹50 crores of methyl vanillin already in stock.
• The strategy is to wait out the Chinese: Management calls competing with Chinese on price "a futile exercise and a bad long-term strategy," betting instead that Chinese producers cannot sustain loss-making production indefinitely and that pricing will stabilize around the \$10 mark.
• Customer de-risking is the structural tailwind: Large flavor and fragrance houses want to diversify away from single-geography dependence on China, and management believes India will capture a large chunk of that alternative-supplier opportunity, particularly in Europe where sustainability concerns add urgency.
• The payback math has stretched: Originally projected at 3 years, the vanillin plant payback is now 4–5 years due to market conditions. Management expects pre-COVID (2019) pricing to normalize in the next few quarters once destocking ends and capacity utilization returns to 2019 levels.
• Bids are the near-term catalyst: The company has qualified to bid for most of the top 10 flavor and fragrance houses' outsourced contracts, with closure expected in the next 30–45 days. If even 30–50% of bids are awarded, capacity utilization can ramp quickly, with supplies beginning January.
• FY26 ambition: Management targets ₹500 crores in vanillin revenue and at least 90% capacity utilization within two years.

Momaya: "The point is that how much will the Chinese continue to produce and lose money and for how long? So that is the reason why we believe that it will kind of equalize and it will come to a level where the pricing should stabilize at this \$10 mark."

Blends: The Steady Engine

• Excellent growth across key geographies: The blends business delivered strong performance driven by stabilization of North American and Brazilian subsidiaries, with CFS Mexico now supporting North American service delivery.
• Sticky revenue from pet food and rendering: Roughly 60% of the US and North America blends business serves the pet food and rendering industry, where the right to win was built on service offerings, delivery systems, and equipment, not just price.
• Brazil is a margin story: Steady revenue and margin improvement followed a revised execution strategy focused on higher-margin products, leaner teams, and an extensive cost-reduction program. The company holds 50–60% market share in Brazil's biodiesel antioxidant market.
• Blends mix is temporarily elevated: At 40%+ of revenue in the first half, the blends share is partly a function of the performance chemicals collapse in Europe. Long term, management expects blends to settle between 30–40% of the mix.
• New markets opening: The company is launching products in Vietnam and Thailand for the aqua feed market and developing channels in Europe and Africa for animal nutrition, with European breakthroughs expected in the next couple of quarters.
• Growth trajectory: Management believes the blends business can sustain 25–30% growth, supported by the biodiesel antioxidant opportunity where Camlin currently holds about \$6 million of an estimated \$40 million total addressable market.

Momaya: "The right to win we got really was not necessarily price driven. Of course, there were some price advantages, but we also focused on our offerings of service, our offerings of delivery systems, equipment, and it was a combination of many factors which led to this right to win."

Europe: Shutdown, Restructuring, and a Possible Restart

• The Italy shutdown gutted revenue: CFS Europe revenue collapsed to ₹42 crores from ₹112 crores in Q1 and ₹155 crores in Q2 FY23, the single largest driver of the consolidated 16% YoY decline. The Diphenol facility is temporarily suspended while management monitors market dynamics.
• A conversion plan is taking shape: Management sees an opportunity to convert the Italy plant into a multipurpose facility producing Hydroquinone, Catechol, and on a campaign basis, MEHQ and Guaiacol from Anisole. A concrete proposal is expected in the next few quarters.
• Hydroquinone prices are firming: Prices have begun to strengthen in the current quarter, and management sees a possible window to restart the Italy plant as early as Q4 FY24 if the trend holds.
• Cost mitigation underway: The company is actively working to reduce fixed costs during the shutdown period while exploring alternative uses for the asset.
• Catechol oversupply is a separate problem: Even with the Italy plant offline, the global catechol market remains significantly oversupplied, meaning the shutdown alone will not lift vanillin prices.

Margins Under Pressure

• Gross margin compressed to 44.9%: The decline was driven primarily by volume reduction and selling-price softness on weak demand. Raw material prices moved down but the fall in selling prices outpaced that reduction.
• EBITDA severely impacted: Operating Forex-adjusted EBITDA fell to 7.8% of revenue, hit by the gross margin decline plus the fixed-cost burden of the capitalized vanillin plant.
• Depreciation and interest are structural drags: Both rose due to the January 2023 capitalization of the composite vanillin plant and recognition of interest on foreign currency long-term loans used to fund it. These costs will persist until vanillin revenue scales.
• Raw material tailwind is uncertain: Key inputs like phenol (now \$1.00/kg vs a \$1.50 peak), hydrogen peroxide, caustic, and glyoxalic acid are all at much lower levels than three years ago, but management cautions that a crude-price spike from Middle East instability could compress margins in the short term, since passing through prices takes roughly a quarter.
• Is this the bottom? Management declined to call a floor, noting that while raw material prices have been stable for a few weeks, visibility is limited. On the sales side, slight improvement is expected from Q4 onwards.

Balance Sheet & Strategic Updates

• Debt reduction via conversion: Total net debt improved from ₹680 crores to ₹565 crores following the conversion of US\$15 million in FCCBs issued to IFC. The company will follow its existing debt structure for now and declined to commit to a debt-free timeline, citing market uncertainty.
• Univar Solutions partnership: Appointed for vanillin distribution in North America's food and beverage segment. A couple of containers have been supplied, with reordering expected in the next 30–45 days.
• CFS Wanglong progressing: The approval procedure for change of use to Heliotropin, an aromatic downstream product of catechol, has substantially advanced. A restart is contemplated in the second half of the next financial year.
• Lockheed Martin: Small-scale commercial orders are being supplied for NegoLyte. Scaling up requires a new, substantially larger plant, with discussions ongoing about who will fund the investment. The opportunity could ultimately become a 5,000–10,000 ton business over a couple of years.
• Management declined to provide granular detail: When analysts asked for volume and price breakdowns across categories and cost-of-production splits for vanillin, management declined on competitive grounds, and also declined to quantify pricing normalization across the company's 40-product portfolio.

Guidance & Commitments

Key Metrics